Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 14/20 | 0.44 |
| ▸ | CASP6 | P55212 | 13/20 | 0.44 |
| ▸ | CASP8 | Q14790 | 13/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10068467 | 0.87 | CASP3 (0.56) | CASP3CASP6CASP8MEN1RAB9A | |
| SCHEMBL4311125 | 0.87 | CASP3 (0.56) | CASP3CASP6CASP8MEN1RAB9A | |
| SCHEMBL644624 | 0.79 | CASP1 (0.48) | CASP3CASP6CASP8 | |
| SCHEMBL645654 | 0.79 | CASP1 (0.48) | CASP3CASP6CASP8 | |
| SCHEMBL4777378 | 0.77 | CYP2D6 (0.35) | — | |
| SCHEMBL11240891 | 0.73 | L3MBTL1 (0.50) | MEN1RAB9AKMT2AL3MBTL1LMNA | |
| SCHEMBL3893622 | 0.73 | ITGB1 (0.55) | CASP3CASP6CASP8 | |
| SCHEMBL3893628 | 0.73 | ITGB1 (0.55) | CASP3CASP6CASP8 | |
| SCHEMBL4557779 | 0.73 | HDAC3 (0.40) | — | |
| SCHEMBL646336 | 0.72 | ELANE (0.53) | CASP3CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337853-B1 | AN EXTENDED TETHERING APPROACH FOR RAPID IDENTIFICATION OF LIGANDS | SUNESIS PHARMACEUTICALS INC (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080261831-A1 | Ligands and libraries of ligands | WELLS JIM | 2008-10-23 | — | — | US | disclosed |
| EP-1836129-B1 | IMPROVED DISPENSER FOR A TABLET, AND METHODS FOR USE | RECKITT BENCKISER INC (US) | 2008-09-10 | — | — | EP | disclosed |
| EP-1939625-A2 | Methods for ligand discovery | Sunesis Pharmaceuticals, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1441228-B1 | An extended tethering approach for rapid identification of ligands | SUNESIS PHARMACEUTICALS INC (US) | 2006-06-28 | — | — | EP | disclosed |
| US-6998233-B2 | Methods for ligand discovery | SUNESIS PHARMACEUTICALS, INC. (US) | 2006-02-14 | — | — | US | disclosed |
| US-20050186630-A1 | Extended tethering approach for rapid identification of ligands | ERLANSON DANIEL A (US) | 2005-08-25 | — | — | US | disclosed |
| US-6919178-B2 | Extended tethering approach for rapid identification of ligands | SUNESIS PHARMACEUTICALS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050142614-A1 | Methods for ligand discovery | WELLS JIM (US) | 2005-06-30 | — | — | US | disclosed |
| EP-1441228-A1 | An extended tethering approach for rapid identification of ligands | Sunesis Pharmaceuticals, Inc. (US) | 2004-07-28 | — | — | EP | disclosed |
| US-20040043426-A1 | Methods for ligand discovery | WELLS JIM (US) | 2004-03-04 | — | — | US | disclosed |
| EP-1337853-A2 | AN EXTENDED TETHERING APPROACH FOR RAPID IDENTIFICATION OF LIGANDS | Sunesis Pharmaceuticals, Inc. (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20020155505-A1 | Methods for ligand discovery | SUNESIS PHARMACEUTICALS, INC. | 2002-10-24 | — | — | US | disclosed |
| US-20020150947-A1 | Extended tethering approach for rapid identification of ligands | SUNESIS PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | disclosed |
| WO-2002042773-A2 | AN EXTENDED TETHERING APPROACH FOR RAPID IDENTIFICATION OF LIGANDS | SUNESIS PHARMACEUTICALS, INC. (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043426-A1 | Methods for ligand discovery | ADGRF1, VCAM1, LDLR | CASP3 4502/4885CASP6 3348/4885CASP8 4562/4885 |
| US-20020155505-A1 | Methods for ligand discovery | ADGRF1, VCAM1, LDLR | CASP3 4502/4885CASP6 3348/4885CASP8 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.